VEGF Trap-Eye Noninferior to Ranibizumab in Two Phase 3 Trials
In patients with wet age-related macular degeneration
(AMD), all regimens of aflibercept (VEGF Trap-
Eye, Regeneron), including aflibercept dosed every
2 months, achieved the primary endpoint compared
with ranibizumab (Lucentis, Genentech) dosed every
month, according to the results of two parallel phase
3 studies rep...